A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy

Seizure

Volumn 9, Issue 2, 2000, Pages 80-87

  Betts, T ^a   Waegemans, T ^b   Crawford, P ^c  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UCB PHARMA   (Belgium)

^c YORK HOSPITAL   (United Kingdom)

Author keywords

Add on therapy; Antiepileptic drugs; Levetiracetam; Refractory epilepsy; Seizures; Titration

Indexed keywords

ETIRACETAM; PLACEBO;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; EPILEPSY; FEMALE; FOCAL EPILEPSY; GRAND MAL SEIZURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; TITRIMETRY; VERTIGO;

EID: 0034162331     PISSN: 10591311     EISSN: None     Source Type: Journal    
DOI: 10.1053/seiz.2000.0380     Document Type: Article

References (13)

1. Perucca E. The new generation of antiepileptic drugs: advantages and disadvantages. British Journal of Clinical Pharmacology. 42:1996;531-543.
2. Mattson R. H., Cramer J. A., Collins J. F. et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. New England Journal of Medicine. 313:1985;145-151.
3. Löscher W., Schmidt D. New drugs for the treatment of epilepsy. Current Opinion Investigating Drugs. 2:1993;1067-1095.
4. Mattson R. H., Cramer J. A., Collins J. F. Early tolerance to antiepileptic drug side effects: a controlled trial of 247 patients. Tolerance to Beneficial and Adverse Effects of Antiepileptic Drugs. (Eds W. P. Koella et al.). 1986;Raven Press, New York. p. 149-156.
5. thedition. 1992;122-143 Elsevier, Amsterdam.
6. Löscher W., Hönack D. Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats. European Journal of Pharmacoogy. 32:1993;147-158.
7. Klitgaard H., Matagne A., Gobert J., Wülfert E. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. European Journal of Pharmacology. 353:1998;191-206.
8. Gower A. J., Hirsch E., Boehrer A., Noyer M., Marescaux C. Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy. Epilepsy Research. 22:1995;207-213.
9. Löscher W., Hönack D., Rundfeldt C. Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy. Journal of Pharmacology and Experimental Therapeutics. 284:1998;474-479.
10. Noyer M., Gillard M., Matagne A., Hénichart J. P., Wülfert E. The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes. European Journal of Pharmacology. 286:1995;137-146.
11. Perucca E., Bialer M. The clinical pharmacokinetics of the newer antiepileptic drugs: focus on topiramate, zonisamide, and tiagabine. Clinical Pharmacokinetics. 31:1996;29-46.
12. Sharief M. K., Singh P., Sander J. W. A. S., Patsalos P. N., Shorvon S. D. Efficacy and tolerability study of ucb L059 in patients with refractory epilepsy. Journal of Epilepsy. 9:1996;106-112.
13. Epilepsia. 22:1981;489-501.